CD274 and non-small cell lung carcinoma: The PD-L1 status was neither predictive in terms of PFS (PD-L1+: 3.1 months [95%CI: 2.8-NA]; PD-L1-: 3.0 months [95%CI: 2.9-NA]; HR 0.74 [95%CI: 0.31-1.65], p=0.424; Figure 2A), nor in terms of OS (PD-L1+: 11.2 months [95%CI: 9.4-NA]; PD-L1-: 13.6 months [95%CI: 8.9-NA]; HR 0.93 [95%CI: 0.30-2.88], p=0.897; Figure 2B) in the entire non-squamous NSCLC cohort.